Gerard Dynes, MD
Neurology · Baton Rouge, LANPI 1053344325
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 76.0% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $724, more than ten times the $26 reported in 2019. That places this record below the midpoint for neurology clinicians in LA, where the typical reported total is $2,263.
Across 175 payments — averaging $10.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$70
- Lundbeck LLC$55
- Novartis$46
- Argenx US, Inc.$44
- Johnson & Johnson$40
- plus $173 from 8 others
What the payments were for
- Food & beverage$1,75798%
- Education$292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 151 | $1,358 |
| Pfizer | 4 | $70 |
| Lundbeck LLC | 3 | $55 |
| Novartis | 3 | $46 |
| Argenx US, Inc. | 2 | $44 |
| Johnson & Johnson(2 entities) | 2 | $40 |
| AstraZeneca | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| C2n Diagnostics, LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Amgen | 1 | $13 |
| CSL Behring | 1 | $11 |
How this compares
$1,786 in reported general payments places this provider in the 45th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $480,462 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 19 | $172,072 |
| Aimovig AutoinjectorErenumab-Aooe | 73 | $100,083 |
| Dimethyl Fumarate | 21 | $86,008 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 15 | $82,899 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $75,892 |
| CopaxoneGlatiramer Acetate | 11 | $73,756 |
| NuplazidPimavanserin Tartrate | 13 | $63,127 |
| Nurtec OdtRimegepant Sulfate | 24 | $30,075 |
| Emgality PenGalcanezumab-Gnlm | 26 | $24,261 |
| RytaryCarbidopa/Levodopa | 15 | $20,537 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 37 | $18,309 |
| Trientine Hcl | 13 | $18,272 |
| Memantine Hcl | 721 | $16,857 |
| QuliptaAtogepant | 11 | $13,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $11 | $172,07219 claims |
| PfizerOctagam, Nurtec Odt, Dilantin | $70 | $117,99961 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $18 | $73,75611 claims |
| AbbVieQulipta | $1,358 | $13,52311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 225 neurology providers in Louisiana.
Other neurology in Baton Rouge
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
- Benjamin KidderBaton Rouge$35K
- Joseph AcostaBaton Rouge$33K
- Jon OlsonBaton Rouge$19K
- William GladneyBaton Rouge$19K
- David GlossBaton Rouge$15K
- Meghan HarrisShreveport$553K
- Maria Carmen WilsonCovington$295K
- John EnglandNew Orleans$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.